SCHEMBL4040047

SCHEMBL4040047

O=S(=O)(Cl)n1ccnc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL20449039 0.89 HTT (0.46)
SCHEMBL1157477 0.79 HTT (0.58)
SCHEMBL6300741 0.79 HTT (0.58)
Ammonia Solution, Strong SCHEMBL18151740 0.77 HTT (0.56)
SCHEMBL9799907 0.77
SCHEMBL13284444 0.76 HTT (0.46)
SCHEMBL1439963 0.75
SCHEMBL21034076 0.75
SCHEMBL27532488 0.75
SCHEMBL187487 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103347909-B In order to prepare precursor compound of being connected on the radiopharmaceutic solid carrier of 18F and preparation method and application 未来化学株式会社 2016-08-10 CN claimed
CN-103193858-B The synthetic method of spiranostan glycoalkaloid 中国海洋大学 2016-08-03 CN claimed
CN-108570053-A Five yuan and 6-membered heterocyclic compound, preparation method, intermediate, combination and application 中国科学院上海药物研究所 2018-09-25 CN disclosed
CN-103347909-B In order to prepare precursor compound of being connected on the radiopharmaceutic solid carrier of 18F and preparation method and application 未来化学株式会社 2016-08-10 CN disclosed
CN-103193858-B The synthetic method of spiranostan glycoalkaloid 中国海洋大学 2016-08-03 CN disclosed
EP-1463728-B1 FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION BRISTOL MYERS SQUIBB CO (US) 2009-01-14 EP disclosed
US-7432267-B2 Fused cyclic modulators of nuclear hormone receptor function BRISTOL-MYERS SQUIBB COMAPNY (US) 2008-10-07 US disclosed
US-7001911-B2 Fused cyclic modulators of nuclear hormone receptor function BRISTOL-MYERS SQUIBB COMPANY (US) 2006-02-21 US disclosed
US-20050282813-A1 Fused cyclic modulators of nuclear hormone receptor function SALVATI MARK E 2005-12-22 US disclosed
EP-1463728-A4 FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION BRISTOL MYERS SQUIBB CO (US) 2005-12-21 EP disclosed
CN-1708500-A Derivatives of [6, 7-dihydro-5H-imidazo [1, 2-alpha ] imidazole-3-sulfonylamino ] -propionamide and their use as inhibitors of the interaction between CAMs and white integrins BOEHRINGER INGELHEIM PHARMA (US) 2005-12-14 CN disclosed
CN-1454083-A Selective androgen receptor modulators and methods of identification, design and use thereof BRISTOL MYERS SQUIBB CO (US) 2003-11-05 CN disclosed
WO-2003053354-A2 FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-03 WO disclosed
US-20030114420-A1 Fused cyclic modulators of nuclear hormone receptor function BRISTOL-MYERS SQUIBB COMPANY 2003-06-19 US disclosed
EP-1299385-A2 FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION Bristol-Myers Squibb Company (US) 2003-04-09 EP disclosed
EP-1299094-A2 SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR IDENTIFICATION, DESIGN AND USE Bristol-Myers Squibb Company (US) 2003-04-09 EP disclosed
US-20020173445-A1 Selective androgen receptor modulators and methods for their identification, design and use BRISTOL-MYERS SQUIBB COMPANY 2002-11-21 US disclosed
WO-2002000617-A2 SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR IDENTIFICATION, DESIGN AND USE BRISTOL-MYERS SQUIBB COMPANY (US) 2002-01-03 WO disclosed
WO-2002000653-A2 FUSED CYCLIC COMPOUNDS AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2002-01-03 WO disclosed
CN-1232451-A Substd. cyclic amine metalloprotease inhibitors PROCTER & GAMBLE (US) 1999-10-20 CN disclosed